In the second part of the study the therapeutic effectiveness of the combined radio-gene therapy with p21 promoter controlling the expression of the therapeutic gene Il-12 was evaluated in a relatively radioresistant and IL-12 resistant TS/A tumor model [42,43]. This evidence concerns the gene CDKN1A and neoplasm.